Edesa Biotech Inc (EDSA) Stock Price, Quote & News

Company Profile

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic aller...

Industry: Biotechnology

Sector: Healthcare

Phone: 289 800 9600

Website: www.edesabiotech.com

Address:

100 Spy Court, Markham, Canada

EireTrader Aug. 27 at 12:31 PM

$EDSA Melanie Jolys funding annoucement today is back in our sector Hopefully they are keeping the best for last

2 · Reply

EDSA2Chap11 Aug. 26 at 4:52 PM

$EDSA Today has the pre PR leak rise feel about it. Something coming AHs!?

1 · Reply

EireTrader Aug. 25 at 5:23 PM

$EDSA ... Perhaps the window for a NOC/c annoucement has just opened 🤔

1 · Reply

EDSA2Chap11 Aug. 25 at 2:19 PM

$EDSA It's hard to avoid two diametrically opposed viewpoints on Edesa Biotech. Paridiprubart is SOLD or at the very least contracts near signing. EDSA management are bigging up their other P3 asset and Paridiprubart gets a begrudging mention and is not prominent on the investor deck. This means $$$$$$ soon. OR Management have put it on the backburner and it will be another 2 or so years before anything substantial, possibly from BARD P2. That means ZZZZZZZZZZ I'm veering on Bullish, but not OVERLY So...

1 · Reply

GoodNewsBull Aug. 24 at 2:53 PM

$BABA NOTE: Whenever you see a annoying Peram-Bear posting on ST always check their stream to find out what made them so angry, you will always find they lost money at some point and they now hate the wordl & everyone in it. Its always the same, never fails He bought all losing stocks for the past 5 years & now wants to share his misery with us. Im guessing buying & putting his "whole net worth" into $EDSA at $50 in 2021 & then adding to his $LOGC shares didnt work out so well. Just sayin

2 · Reply

ZacksSCR Aug. 24 at 2:10 PM

$EDSA New Approach to Treating Vitiligo https://scr.zacks.com/news/news-details/2026/EDSA-Recruitment-in-Phase-2-Vitiligo-Study-Set-to-Get-Underway-article/default.aspx

1 · Reply

JoeDomiano Aug. 23 at 8:59 PM

$EDSA Fully funded for EB05 and EB06. 2027 is going to be a great year!

1 · Reply

EDSA2Chap11 Aug. 22 at 7:09 AM

$EDSA Below $5. A penny stock once more.

1 · Reply

JoeDomiano Aug. 21 at 7:12 PM

$EDSA

1 · Reply

EdV3 Aug. 21 at 3:19 PM

$EDSA i think the capital raise all things considered was not bad. For the company it's a win, for investors at least an immediate financing overhang is removed. now, one would simply ask after 18 months and burning thru essentially all the Velan money, why there is still no fpi or approved ind? Can this money get them to a p2 readout? No, not in my view. But probably close. Paridiprubart would have been scooped up by now if big pharma saw a legit opportunity but you're going to have to wait for JB data now. The chart is showing perhaps one of the nastiest head and shoulder patterns I've ever seen but hey that doesn't really mean anything...right? Back on my watchlist for now. I've always liked EB06.

1 · Reply

Edesa Biotech 3.87M share Spot Secondary priced at $5.50

Aug 19, 2026, 10:20 PM EDT - 10 days ago

Edesa Biotech Announces Pricing of $25.0 Million Public Offering

2026-08-19T20:05:28.000Z - 10 days ago

Edesa Biotech announces offering of common stock and warrants, no amount given

Aug 19, 2026, 4:01 PM EDT - 10 days ago

Edesa Biotech Announces Proposed Public Offering

Aug 13, 2026, 4:15 PM EDT - 16 days ago

Edesa Biotech Reports Fiscal 3rd Quarter 2026 Results

2026-07-02T21:05:18.000Z - 2 months ago

Edesa Biotech files to sell 729,241 common shares for holders

2026-06-29T19:50:30.000Z - 2 months ago

Edesa Biotech reinstated with a Buy at Brookline

2026-06-11T13:27:38.000Z - 2 months ago

Edesa Biotech announces $3.5M private placement

Jun 11, 2026, 9:15 AM EDT - 2 months ago

Edesa Biotech Announces $3.5 Million Private Placement of Common Shares Led by CEO and Healthcare-Focused Investors

Jun 5, 2026, 9:20 AM EDT - 3 months ago

Edesa Biotech Reports Positive Exploratory Data for Paridiprubart in Patients with Acute Kidney Injury

2026-05-19T13:40:50.000Z - 3 months ago

Edesa Biotech Inc trading resumes

2026-05-19T13:35:48.000Z - 3 months ago

Edesa Biotech Inc trading halted, volatility trading pause

May 19, 2026, 9:15 AM EDT - 3 months ago

Edesa Biotech to Present New Data on Paridiprubart in Acute Kidney Injury at European Nephrology Conference

May 14, 2026, 4:30 PM EDT - 3 months ago

Edesa Biotech Reports Fiscal 2nd Quarter 2026 Results

2026-04-28T14:26:55.000Z - 4 months ago

Edesa Biotech Inc trading halted, volatility trading pause

2026-04-28T14:20:13.000Z - 4 months ago

Edesa Biotech Inc trading resumes

Mar 31, 2026, 4:20 PM EDT - 5 months ago

Edesa Biotech Invited for Oral Showcase at Respiratory Innovation Summit

2026-03-26T13:37:21.000Z - 5 months ago

Edesa Biotech provides update on EB06 clinical study

Mar 26, 2026, 9:15 AM EDT - 5 months ago

Edesa Biotech Advances Vitiligo Program for Planned Mid-2026 Enrollment

2026-02-24T14:20:13.000Z - 6 months ago

Edesa Biotech reports additional results from Phase 3 paridiprubart study

Feb 24, 2026, 9:15 AM EST - 6 months ago

Edesa Biotech Reports Additional Positive Results from Phase 3 Paridiprubart Study

2026-02-13T21:25:18.000Z - 7 months ago

Edesa Biotech reports Q1 EPS (28c), consensus (45c)

Feb 13, 2026, 4:20 PM EST - 7 months ago

Edesa Biotech Reports Fiscal 1st Quarter 2026 Results

Dec 12, 2025, 4:20 PM EST - 9 months ago

Edesa Biotech Reports Fiscal Year 2025 Results

Oct 31, 2025, 4:30 PM EDT - 10 months ago

Edesa Biotech Announces Upcoming Conference Schedule

2025-10-28T11:55:48.000Z - 10 months ago

Edesa Biotech announces Phase 3 study of paridiprubart met primary endpoint

Oct 28, 2025, 7:45 AM EDT - 10 months ago

Edesa Biotech Reports Positive Results in Phase 3 Respiratory Study

Aug 8, 2025, 4:35 PM EDT - 1 year ago

Edesa Biotech Reports Fiscal 3rd Quarter 2025 Results

2025-07-25T20:50:18.000Z - 1 year ago

Edesa Biotech files $150M mixed securities shelf

2025-06-27T14:35:08.000Z - 1 year ago

Edesa Biotech assumed with a Buy at H.C. Wainwright

2025-05-23T10:55:53.000Z - 1 year ago

Edesa Biotech initiated with a Buy at Lucid Capital

May 14, 2025, 4:15 PM EDT - 1 year ago

Edesa Biotech Reports Fiscal 2nd Quarter 2025 Results

Apr 28, 2025, 4:30 PM EDT - 1 year ago

Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference

2025-04-04T20:20:09.000Z - 1 year ago

Edesa Biotech says Peter Weiler to succeed Stephen Lemieux as CFO

Apr 4, 2025, 4:15 PM EDT - 1 year ago

Edesa Biotech Announces Chief Financial Officer Transition

2025-03-04T21:36:26.000Z - 1 year ago

Edesa Biotech files to sell 7.81M common shares for holders

Feb 14, 2025, 4:15 PM EST - 1 year ago

Edesa Biotech Reports Fiscal 1st Quarter 2025 Results

Feb 13, 2025, 7:00 AM EST - 1 year ago

Edesa Biotech Announces $15.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Dec 13, 2024, 4:30 PM EST - 1 year ago

Edesa Biotech Reports Fiscal Year 2024 Results

Oct 31, 2024, 8:15 AM EDT - 1 year ago

Edesa Biotech's Founder Makes Strategic Investment in the Company

Sep 13, 2024, 7:38 PM EDT - 2 years ago

Pardeep Nijhawan Provides Update to Beneficial Ownership of Securities of Edesa Biotech, Inc.

Aug 9, 2024, 4:20 PM EDT - 2 years ago

Edesa Biotech Reports Fiscal 3rd Quarter 2024 Results

Jun 24, 2024, 8:20 AM EDT - 2 years ago

BARDA Selects Edesa Biotech's Drug for U.S. Funded Platform Trial in General ARDS

May 10, 2024, 4:15 PM EDT - 2 years ago

Edesa Biotech Reports Fiscal 2nd Quarter 2024 Results

Apr 2, 2024, 9:00 AM EDT - 2 years ago

Edesa Biotech to Participate in Upcoming Investor Conferences

Mar 21, 2024, 4:30 PM EDT - 2 years ago

Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Conference

Mar 7, 2024, 8:45 AM EST - 2 years ago

Edesa Biotech to Participate in Barclays Global Healthcare Conference

Mar 4, 2024, 4:30 PM EST - 2 years ago

Edesa Biotech to Participate in Upcoming Dermatology Meetings

Feb 9, 2024, 4:15 PM EST - 2 years ago

Edesa Biotech Reports Fiscal 1st Quarter 2024 Results

Jan 4, 2024, 4:15 PM EST - 2 years ago

Edesa Biotech to Participate in Dermatology Summit and JP Morgan Week

Dec 15, 2023, 4:10 PM EST - 2 years ago

Edesa Biotech Reports Fiscal Year 2023 Results

Nov 20, 2023, 4:05 PM EST - 3 years ago

Edesa Biotech Reports Final Phase 2b Results for Dermatitis Study

Oct 26, 2023, 4:05 PM EDT - 3 years ago

Edesa Biotech to Present at Dermatology Drug Development Summit

Oct 25, 2023, 9:10 AM EDT - 3 years ago

Regulators Approve Updated Phase 3 Trial Design for Edesa Biotech's ARDS Drug

Oct 12, 2023, 12:15 PM EDT - 3 years ago

Edesa Biotech Secures $10 Million Credit Facility with Company Founder

Oct 12, 2023, 12:10 PM EDT - 3 years ago

Edesa Biotech to Receive Up To C$23 Million in Funding from Federal Government

Oct 10, 2023, 9:00 AM EDT - 3 years ago

Edesa Biotech Announces One-for-Seven Reverse Share Split

Sep 28, 2023, 8:15 AM EDT - 3 years ago

Edesa Biotech Publishes Phase 2 Substudy Results of ARDS Drug Candidate

Aug 9, 2023, 4:15 PM EDT - 3 years ago

Edesa Biotech Reports Fiscal Third Quarter 2023 Results

Jul 26, 2023, 9:00 AM EDT - 3 years ago

Edesa Biotech to Participate in Upcoming Canaccord Genuity Growth Conference

Jun 28, 2023, 7:55 AM EDT - 3 years ago

Edesa Biotech's ARDS Drug Inhibits Inflammation from Influenza and Other Pathogens

Jun 27, 2023, 8:15 AM EDT - 3 years ago

Edesa Biotech Appoints Biotech Deal Veteran to CFO Role

Jun 15, 2023, 8:00 AM EDT - 3 years ago

Edesa Biotech Anti-Inflammatory Drug Candidate Assigned Name

May 11, 2023, 4:30 PM EDT - 3 years ago

Edesa Biotech Reports Fiscal 2nd Quarter 2023 Results

Apr 20, 2023, 8:30 AM EDT - 3 years ago

Edesa Biotech to Participate in Swiss Biotech Day

Apr 4, 2023, 8:45 AM EDT - 3 years ago

The WHO and USAN Adopt Generic Name for Edesa's ARDS Drug Candidate

Mar 23, 2023, 4:30 PM EDT - 3 years ago

Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Disease Conference

Mar 16, 2023, 4:10 PM EDT - 3 years ago

Edesa Biotech to Present Favorable Dermatitis Drug Results at American Academy of Dermatology Association Annual Meeting

EireTrader Aug. 27 at 12:31 PM

$EDSA Melanie Jolys funding annoucement today is back in our sector Hopefully they are keeping the best for last

2 · Reply

EDSA2Chap11 Aug. 26 at 4:52 PM

$EDSA Today has the pre PR leak rise feel about it. Something coming AHs!?

1 · Reply

EireTrader Aug. 25 at 5:23 PM

$EDSA ... Perhaps the window for a NOC/c annoucement has just opened 🤔

1 · Reply

EDSA2Chap11 Aug. 25 at 2:19 PM

1 · Reply

GoodNewsBull Aug. 24 at 2:53 PM

2 · Reply

ZacksSCR Aug. 24 at 2:10 PM

$EDSA New Approach to Treating Vitiligo https://scr.zacks.com/news/news-details/2026/EDSA-Recruitment-in-Phase-2-Vitiligo-Study-Set-to-Get-Underway-article/default.aspx

1 · Reply

JoeDomiano Aug. 23 at 8:59 PM

$EDSA Fully funded for EB05 and EB06. 2027 is going to be a great year!

1 · Reply

EDSA2Chap11 Aug. 22 at 7:09 AM

$EDSA Below $5. A penny stock once more.

1 · Reply

JoeDomiano Aug. 21 at 7:12 PM

$EDSA

1 · Reply

EdV3 Aug. 21 at 3:19 PM

1 · Reply

topstockalerts Aug. 21 at 12:12 PM

Pre Market Top Gainers PT2 $YJ $KNRX $EDSA $USDE.X $SNSC

0 · Reply

GaryMelon Aug. 20 at 8:41 PM

$EDSA Bought 5k more today 🤷‍♂️

1 · Reply

Boywithathorn Aug. 20 at 8:34 PM

$EDSA just where Kumar Pardeep Nijhawan belongs.

0 · Reply

Boywithathorn Aug. 20 at 8:26 PM

$EDSA yep. This company should be delisted and Par and his cronies jailed! 👎🏿

0 · Reply

stockzorg Aug. 20 at 8:23 PM

$EDSA So 69 days after the CEO and some institutional patsy bagholder get a "great price" they are now all underwater via a public offering. Could not be more amused. My buy offer is in at $0.71 Particularly funny is the warrant expiration if top line EB06 data is released within 18 months. I hope no one is holding their breath with no O2 close at hand. We should have an over/under competition for dates of EB06 data release, first shareholder lawsuit, regulator action, etc. That would be more intereresting than watching this management team wet the bed.

1 · Reply

Boywithathorn Aug. 20 at 8:02 PM

$EDSA The most hated soft country in all The land struck again. Hijacking good drugs and just asleep at the wheel ruing shareholders. Not an ounce to balls in any Canadian I’ve ever seen. Sad shite.

0 · Reply

OpenOutcrier Aug. 20 at 12:56 PM

$EDSA (-11.5% pre) Edesa Biotech prices $25M public offering on Nasdaq https://ooc.bz/l/111769

0 · Reply

juliano777 Aug. 20 at 9:28 AM

$EDSA There are buyers at $5.50, whereas a few months ago it was worth less than $1. That’s a really good sign. They’ll now have enough cash to last 18 months... I think it’s an opportunity.

0 · Reply

maurizio58 Aug. 20 at 9:22 AM

$EDSA https://www.globenewswire.com/news-release/2026/08/20/3348070/0/en/edesa-biotech-announces-pricing-of-25-0-million-public-offering.html?print=1

0 · Reply

Treb3k Aug. 20 at 3:49 AM

$EDSA who had ”bad dilution”?

1 · Reply

EdV3 Aug. 20 at 3:20 AM

$EDSA did Par "Par"ticipate?

1 · Reply

focafoca99 Aug. 20 at 3:09 AM

$EDSA priced a $25.0 million public offering of common shares and warrants.

0 · Reply

Market Cap	44.54M
Revenue (ttm)	0.00
Net Income (ttm)	-7.19M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	70,600
Avg Vol	86,474
Day's Range	N/A - N/A
Shares Out	9.64M
Stochastic %K	23%
Beta	1.08
Analysts	Strong Sell
Price Target	$16.33